Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2086


Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?

Malek V, Gaikwad AB.

Biomed Pharmacother. 2017 Jun;90:752-759. doi: 10.1016/j.biopha.2017.04.024. Epub 2017 Apr 15. Review.


The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis.

Liao KM, Cheng HT, Lee YH, Chen CY.

Medicine (Baltimore). 2017 Mar;96(13):e6525. doi: 10.1097/MD.0000000000006525.


Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study.

Schmidt M, Mansfield KE, Bhaskaran K, Nitsch D, Sørensen HT, Smeeth L, Tomlinson LA.

BMJ. 2017 Mar 9;356:j791. doi: 10.1136/bmj.j791.


Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices.

Shafi T, Sozio SM, Luly J, Bandeen-Roche KJ, St Peter WL, Ephraim PL, McDermott A, Herzog CA, Crews DC, Scialla JJ, Tangri N, Miskulin DC, Michels WM, Jaar BG, Zager PG, Meyer KB, Wu AW, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators..

Medicine (Baltimore). 2017 Feb;96(5):e5924. doi: 10.1097/MD.0000000000005924.


Delayed onset of posterior reversible encephalopathy syndrome in a case of scleroderma renal crisis with maintenance hemodialysis: Case report and literature review.

Chen CY, Hung SY, Lee YJ, Lin YC, Pai CC.

Medicine (Baltimore). 2016 Dec;95(52):e5725. doi: 10.1097/MD.0000000000005725. Review.


Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients.

Shireman TI, Mahnken JD, Phadnis MA, Ellerbeck EF, Wetmore JB.

Kidney Blood Press Res. 2016;41(6):873-885. doi: 10.1159/000452590. Epub 2016 Nov 21.


Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.

Makam RC, Erskine N, McManus DD, Lessard D, Gore JM, Yarzebski J, Goldberg RJ.

Am J Cardiol. 2016 Dec 15;118(12):1792-1797. doi: 10.1016/j.amjcard.2016.08.065. Epub 2016 Sep 13.


[Aldosterone antagonists for preventing the progression of chronic kidney disease].

Schmidt S, Spek A.

Urologe A. 2016 Oct;55(10):1360-1363. German. No abstract available.


Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial.

Xu X, Qin X, Li Y, Sun D, Wang J, Liang M, Wang B, Huo Y, Hou FF; investigators of the Renal Substudy of the China Stroke Primary Prevention Trial (CSPPT)..

JAMA Intern Med. 2016 Oct 1;176(10):1443-1450. doi: 10.1001/jamainternmed.2016.4687.


Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?

Ahmed A, Jorna T, Bhandari S.

Nephron. 2016;133(3):147-58. doi: 10.1159/000447068. Epub 2016 Jun 24. Review.


Alport Syndrome in Women and Girls.

Savige J, Colville D, Rheault M, Gear S, Lennon R, Lagas S, Finlay M, Flinter F.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1713-20. doi: 10.2215/CJN.00580116. Epub 2016 Jun 10.


Role of Renal Oxidative Stress in the Pathogenesis of the Cardiorenal Syndrome.

Giam B, Kaye DM, Rajapakse NW.

Heart Lung Circ. 2016 Aug;25(8):874-80. doi: 10.1016/j.hlc.2016.02.022. Epub 2016 Apr 16. Review.


Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function?

Carson C, Al-Makki A, Shepler B.

J Pharm Pharm Sci. 2016;19(1):1-7. doi: 10.18433/J3K020. Review.


Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.

Zhao HJ, Li Y, Liu SM, Sun XG, Li M, Hao Y, Cui LQ, Wang AH.

Ren Fail. 2016 Jul;38(6):849-56. doi: 10.3109/0886022X.2016.1165065. Epub 2016 Apr 7. Review.


A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.

Wu LS, Chang SH, Chang GJ, Liu JR, Chan YH, Lee HF, Wen MS, Chen WJ, Yeh YH, Kuo CT, See LC.

Cardiovasc Diabetol. 2016 Apr 2;15:56. doi: 10.1186/s12933-016-0365-x.


The effects of cytotoxic therapy in progressive IgA nephropathy.

Shin JH, Lee JE, Park JH, Lim S, Jang HR, Kwon GY, Huh W, Jung SH, Kim YG, Oh HY, Kim DJ.

Ann Med. 2016;48(3):171-81. doi: 10.3109/07853890.2016.1153805. Epub 2016 Mar 26.


Clearance of cardiovascular medications during hemodialysis.

Tieu A, Leither M, Urquhart BL, Weir MA.

Curr Opin Nephrol Hypertens. 2016 May;25(3):257-67. doi: 10.1097/MNH.0000000000000216. Review.


Serum tryptase concentration and progression to end-stage renal disease.

Jesky MD, Stringer SJ, Fenton A, Ng KP, Yadav P, Ndumbo M, McCann K, Plant T, Dasgupta I, Harding SJ, Drayson MT, Redegeld F, Ferro CJ, Cockwell P.

Eur J Clin Invest. 2016 May;46(5):460-74. doi: 10.1111/eci.12622. Epub 2016 Apr 15.


Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.

Slomka T, Lennon ES, Akbar H, Gosmanova EO, Bhattacharya SK, Oliphant CS, Khouzam RN.

Am J Med Sci. 2016 Mar;351(3):309-16. doi: 10.1016/j.amjms.2015.12.021. Review.


Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.

Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B.

PLoS Med. 2016 Mar 8;13(3):e1001971. doi: 10.1371/journal.pmed.1001971. eCollection 2016 Mar. Review. Erratum in: PLoS Med. 2016 Jun;13(6):e1002064.

Supplemental Content

Loading ...
Support Center